Azura Ophthalmics — raw details

Highlights

IIA supported (ever)1 patent

About

Ophthalmic Keratolytics

Azura Ophthalmics is utilizing a deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of ophthalmic keratolytics to treat underserved ophthalmic conditions.

Azura has a robust clinical-stage program focused on resolving the pathophysiology of meibomian gland dysfunction and contact lens discomfort. It is Azura's belief that AZR-MD-001 can reverse the core pathophysiology of these conditions, alleviating their signs and symptoms.

Additional areas of focus include the development of the company's novel new chemical entities, which target the pathophysiology of ocular surface diseases with a multi-modal mechanism of action.

Identity

Name	Azura Ophthalmics
Slug	azura-ophthalmics
Type / kind	startup
Crunchbase ID	azura-ophthalmics
Source _id	agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoNTL5oYJDA

Status

Status	active
Last update	2026-05-17

Location

HQ country code	IL
HQ region/district	Center District
HQ city	Tel Aviv-Yafo
HQ address	Druyanov St 5, Tel Aviv-Yafo, Israel

Web & social

Website	https://azuraophthalmics.com/
Careers page	https://azuraophthalmics.com/careers
LinkedIn	https://www.linkedin.com/company/13448320
Twitter / X	https://twitter.com/Azura_Op

Classifications

Primary sector Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

Biologicals

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology

Business models

B2B

Funding

Total raised	$37.2M
Current stage	Series C

Raw source document

Show full JSON (0 KB)

{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}